Management of the refractory vitiligo patient: current therapeutic strategies and future options DOI Creative Commons
Xinju Wang, Wei Wu,

Jianru Chen

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 14

Опубликована: Янв. 4, 2024

Vitiligo is an autoimmune disease that leads to disfiguring depigmented lesions of skin and mucosa. Although effective treatments are available for vitiligo, there still some patients with poor responses conventional treatment. Refractory vitiligo mostly located on exposed sites such as acral lips, leading significant life stress. Understanding the causes refractory developing targeted essential enhance outcomes. In this review, we summarized recent treatment approaches potential methods vitiligo. Janus kinase inhibitors have shown efficacy in A variety surgical interventions fractional carbon dioxide laser been widely applied combination therapies. Furthermore, melanocyte regeneration activation therapies potentially strategies. Patients should be referred psychological monitoring reduce pathogenic effects chronic Finally, depigmentation camouflage may beneficial achieving uniform color improved quality life. Our ultimate focus provide alternative options bring inspiration future research.

Язык: Английский

A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring DOI Creative Commons
Christeen Samuel, Hannah Cornman, Anusha Kambala

и другие.

Dermatology and Therapy, Год журнала: 2023, Номер 13(3), С. 729 - 749

Опубликована: Фев. 15, 2023

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. The US Food and Drug Administration (FDA) recently placed black box warning on this class medications due to safety concerns based data from studies investigating tofacitinib patients rheumatoid arthritis. Here we provide an overview the timeline FDA approval JAK dermatology. We also discuss available profiles approved oral JAK1 inhibitors, namely abrocitinib upadacitinib, baricitinib, JAK1/2 inhibitor, deucravacitinib, Tyk2 topical inhibitor ruxolitinib dermatology patients. Additionally, offer suggestions for initial screening laboratory monitoring receiving inhibitors. found that rates venous thromboembolism reported trials ranged no events 0.1–0.5% dermatology-specific phase 3 clinical compared placebo. cardiovascular 0.4–1.2% 0.5–1.2% serious infections were 0.4–4.8% 0.5–1.3% nonmelanoma skin cancer (NMSC) event 0.6–0.9% non-NMSC 0.2–0.7% 0.6% Most who developed these adverse had risk factors specific event. most common included upper respiratory infections, nasopharyngitis, nausea, headache, acne. Dermatologists should consider patients' baseline developing complications when prescribing

Язык: Английский

Процитировано

123
Skin Pigmentation Types, Causes and Treatment—A Review DOI Creative Commons

Amin Mahmood Thawabteh,

Alaa Jibreen,

Donia Karaman

и другие.

Molecules, Год журнала: 2023, Номер 28(12), С. 4839 - 4839

Опубликована: Июнь 18, 2023

Human skin pigmentation and melanin synthesis are incredibly variable, impacted by genetics, UV exposure, some drugs. Patients' physical appearance, psychological health, social functioning all a sizable number of conditions that cause pigmentary abnormalities. Hyperpigmentation, where pigment appears to overflow, hypopigmentation, is reduced, the two major classifications pigmentation. Albinism, melasma, vitiligo, Addison's disease, post-inflammatory hyperpigmentation, which can be brought on eczema, acne vulgaris, drug interactions, most common disorders in clinical practice. Anti-inflammatory medications, antioxidants, medications inhibit tyrosinase, prevents production melanin, possible treatments for problems. Skin treated orally topically with herbal remedies, cosmetic products, but doctor should always consulted before beginning any new medicine or treatment plan. This review article explores numerous types problems, their causes, treatments, as well 25 plants, 4 marine species, 17 topical oral now market have been clinically tested treat diseases.

Язык: Английский

Процитировано

91
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations DOI Creative Commons
Julien Séneschal, Reinhart Speeckaert, Alain Taı̈eb

и другие.

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2023, Номер 37(11), С. 2185 - 2195

Опубликована: Сен. 15, 2023

The treatment of vitiligo can be challenging. Up-to-date agreed consensus recommendations on the use topical and systemic therapies to facilitate clinical management are currently lacking.To develop internationally agreed-upon expert-based for vitiligo.In this statement, a consortium 42 international experts four patient representatives participated in different online live meetings strategy vitiligo. At least two summarized evidence topics included algorithms. A survey was then given core group eight resolve remaining issues. Subsequently, were finalized validated based further input from entire during meetings.The provided summarize latest regarding (steroids, calcineurin inhibitors Jak-inhibitors) therapies, including steroids other immunomodulating or antioxidant agents. modalities phototherapies (NB-UVB, photochemotherapy, excimer devices home phototherapy), which often combined with also summarized. Interventional approaches as well depigmentation strategies presented specific indications. Finally, status innovative targeted under development is discussed.This statement culminated practice new ongoing vitiligo, will likely improve future disease that still has many unmet needs.

Язык: Английский

Процитировано

61
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story DOI Creative Commons
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati

и другие.

Annals of the Rheumatic Diseases, Год журнала: 2023, Номер 83(2), С. 139 - 160

Опубликована: Ноя. 3, 2023

Fundamental insight gained over the last decades led to discovery of cytokines as pivotal drivers inflammatory diseases such rheumatoid arthritis, psoriasis/psoriasis bowel diseases, atopic dermatitis and spondylarthritis. A deeper understanding pro-inflammatory anti-inflammatory effects various has prompted new cytokine-targeting therapies, which revolutionised treatment options in years for patients with disorders. Disease-associated immune responses typically involve a complex interplay multiple cytokines. Therefore, blockade one single cytokine does not necessarily lead persistent remission all disorders fostered therapeutic strategies targeting intracellular pathways shared by By inhibiting JAK-STAT signalling common families cytokines, JAK-inhibitors (JAKinibs) have created paradigm diseases. Multiple agents been approved more are being investigated several indications. Second-generation selective JAKinibs devised aim achieve an increased selectivity possible reduced risk side effects. In current review, we will summarise body evidence pan versus most recent insights on indications, including COVID-19.

Язык: Английский

Процитировано

55
JAK-STAT pathway inhibitors in dermatology DOI Creative Commons
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro

и другие.

Anais Brasileiros de Dermatologia, Год журнала: 2023, Номер 98(5), С. 656 - 677

Опубликована: Май 23, 2023

The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different patterns have potential indications for various medical conditions. main dermatological targets of inhibitors are inflammatory or autoimmune diseases psoriasis, vitiligo, atopic dermatitis alopecia areata; however, several dermatoses under investigation to expand this list indications. As should gradually occupy a relevant space in prescriptions, review presents the available drugs, their immunological effects, pharmacological characteristics, related clinical efficacy safety, aiming validate best practice.

Язык: Английский

Процитировано

48
JAK inhibitor selectivity: new opportunities, better drugs? DOI
Anniina Virtanen, Francesca Romana Spinelli,

Jean Baptiste Telliez

и другие.

Nature Reviews Rheumatology, Год журнала: 2024, Номер 20(10), С. 649 - 665

Опубликована: Сен. 9, 2024

Язык: Английский

Процитировано

23
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors DOI
Kaitlynne N. Cunningham, David Rosmarin

American Journal of Clinical Dermatology, Год журнала: 2023, Номер 24(2), С. 165 - 186

Опубликована: Янв. 30, 2023

Язык: Английский

Процитировано

39
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments DOI Creative Commons
Svenja Müller, Claudia Zeidler, Sonja Ständer

и другие.

American Journal of Clinical Dermatology, Год журнала: 2023, Номер 25(1), С. 15 - 33

Опубликована: Сен. 17, 2023

Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history repeated scratching. Patients with CPG experience significant psychological burden notable impairment in their quality life. nodular type (CNPG; synonym: nodularis) represents most common subtype CPG. As CNPG representative for all subtypes, we refer this review to both We provide an overview clinical characteristics assessment CPG, disease underlying pathophysiology including associated therapeutic targets. The information provided results from PubMed search latest publications database current trials (ClinicalTrials.gov, EU Clinical Trials Register [European Medicines Agency]; using following terms or combinations terms: 'chronic prurigo', 'prurigo', 'prurigo nodularis', 'pathophysiology', 'therapy', 'biologics', 'treatment'). Dupilumab first authorized systemic therapy European Agency (EMA) US Food Drug Administration (FDA) date. Topical agents are currently under investigation randomized, placebo-controlled phase II III such as biologics (e.g., nemolizumab, vixarelimab/KPL-716, barzolvolimab/CDX-0159), small molecules (ruxolitinib cream, povorcitinib/INCB054707, abrocitinib) opioid modulator nalbuphine highlighted. In last past 15 years, several milestones have been reached regarding understanding transcriptomic analysis, terminology, guideline, approval 2022, which contributed improved medical care affected patients. broad range identified targets, case observations initiated offers possibility more drug approvals near future.

Язык: Английский

Процитировано

36
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases DOI
Jenne P. Ingrassia, Muhammad Haisum Maqsood, Joel M. Gelfand

и другие.

JAMA Dermatology, Год журнала: 2023, Номер 160(1), С. 28 - 28

Опубликована: Ноя. 1, 2023

Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food Drug Administration (FDA) boxed warning label oral topical JAK regarding increased risk of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), serious infections, malignant neoplasm, death. However, this was precipitated by results the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study, which only included rheumatoid arthritis, same association may not be observed in dermatologic conditions.

Язык: Английский

Процитировано

33
A Comprehensive Review on Skin Pigmentation-Types, Causes, and Treatment DOI Open Access

Ameen Mahmood Thawabteh,

Alaa Jibreen,

Donia Karaman

и другие.

Опубликована: Май 10, 2023

Humans have extremely variable skin pigmentation and melanin production influenced by genetics, UV exposure, some medications. A significant number of illnesses that result in pigmentary abnormalities an impact on patients’ physical appearance as well their psychological social well-being. Skin can be divided into two basic categories: hyperpigmentation, where pigment appears to overflow, hypopigmentation, is reduced. Albinism, melasma, vitiligo, Addison's disease, post-inflammatory which brought eczema, acne vulgaris, drug interactions, are the most common disorders clinical practice. Anti-inflammatory medications, antioxidants, medications inhibit tyrosine, prevents melanin, all possible treatments for problems. treated orally topically with herbal remedies, cosmetic products, but a doctor should always consulted before beginning any new medicine or treatment plan. This review article explores numerous types problems, causes, treatments, 25 plants, four marine species, 17 topical oral now market been clinically tested treat diseases.

Язык: Английский

Процитировано

25